デフォルト表紙
市場調査レポート
商品コード
957048

ヒトマイクロバイオームの世界市場

Human Microbiome

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 247 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.41円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

ヒトマイクロバイオームの世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 247 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のヒトマイクロバイオームの市場規模は、分析期間(2020年~2027年)に13.8%のCAGRで成長する見通しで、2020年の3億9,100万米ドルから2027年には9億6,450万米ドルに達すると予測されています。当レポートで分析されているセグメントの1つである急性下痢は、分析期間中に14.9%の年率で成長し、5億2,700万米ドルに達すると予測されています。

当レポートは、世界のヒトマイクロバイオーム市場について調査しており、市場シェア、動向や見通し、成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • DowDuPont, Inc.
  • Enterome SA
  • Merck & Co., Inc.
  • Metabiomics Corporation
  • Microbiome Therapeutics, LLC.
  • Osel, Inc.
  • Second Genome
  • Vedanta Biosciences, Inc.
  • ViThera Pharmaceuticals, Inc.
  • Yakult Honsha Co., Ltd.

目次

I. イントロダクション、調査手法、調査範囲

II. エグゼクティブサマリー

  • 市場概要
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と成長要因
  • 世界市場の見通し

III. 市場分析

  • 地域別市場分析
  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

IV. 競合

  • 企業プロファイル:44社
目次
Product Code: MCP12453

Abstract:

Global Human Microbiome Market to Reach $964.5 Million by 2027

Amid the COVID-19 crisis, the global market for Human Microbiome estimated at US$391 Million in the year 2020, is projected to reach a revised size of US$964.5 Million by 2027, growing at a CAGR of 13.8% over the analysis period 2020-2027. Acute Diarrhea, one of the segments analyzed in the report, is projected to record a 14.9% CAGR and reach US$527 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Obesity segment is readjusted to a revised 12.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $115.6 Million, While China is Forecast to Grow at 13.2% CAGR

The Human Microbiome market in the U.S. is estimated at US$115.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$167.2 Million by the year 2027 trailing a CAGR of 13.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.2% and 11.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10% CAGR.

Diabetes Segment to Record 14.1% CAGR

In the global Diabetes segment, USA, Canada, Japan, China and Europe will drive the 13.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$12 Million in the year 2020 will reach a projected size of US$29.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$114.2 Million by the year 2027.

Select Competitors (Total 46 Featured) -

  • DowDuPont, Inc.
  • Enterome SA
  • Merck & Co., Inc.
  • Metabiomics Corporation
  • Microbiome Therapeutics, LLC.
  • Osel, Inc.
  • Second Genome
  • Vedanta Biosciences, Inc.
  • ViThera Pharmaceuticals, Inc.
  • Yakult Honsha Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Human Microbiome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Human Microbiome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 3: World 15-Year Perspective for Human Microbiome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027
    • TABLE 4: World Current & Future Analysis for Acute Diarrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Acute Diarrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 6: World 15-Year Perspective for Acute Diarrhea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 7: World Current & Future Analysis for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 9: World 15-Year Perspective for Obesity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 10: World Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 12: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 13: World Current & Future Analysis for Autoimmune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Autoimmune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 15: World 15-Year Perspective for Autoimmune Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 16: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 18: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 19: World Current & Future Analysis for Mental Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Mental Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 21: World 15-Year Perspective for Mental Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 22: World Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 25: World Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 27: World 15-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 28: World Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 30: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 31: World Current & Future Analysis for Probiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Probiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 33: World 15-Year Perspective for Probiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 34: World Current & Future Analysis for Prebiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 35: World Historic Review for Prebiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 36: World 15-Year Perspective for Prebiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 37: World Current & Future Analysis for Foods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 38: World Historic Review for Foods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 39: World 15-Year Perspective for Foods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 40: World Current & Future Analysis for Medical Foods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 41: World Historic Review for Medical Foods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 42: World 15-Year Perspective for Medical Foods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 43: World Current & Future Analysis for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 44: World Historic Review for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 45: World 15-Year Perspective for Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 46: World Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 47: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 48: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 49: USA Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 50: USA Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 51: USA 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 52: USA Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 53: USA Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 54: USA 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 55: USA Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 56: USA Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 57: USA 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • CANADA
    • TABLE 58: Canada Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 59: Canada Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 60: Canada 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 61: Canada Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 62: Canada Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 63: Canada 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 64: Canada Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 65: Canada Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 66: Canada 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • JAPAN
    • TABLE 67: Japan Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 68: Japan Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 69: Japan 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 70: Japan Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 71: Japan Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 72: Japan 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 73: Japan Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 74: Japan Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 75: Japan 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • CHINA
    • TABLE 76: China Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 77: China Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 78: China 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 79: China Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 80: China Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 81: China 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 82: China Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 83: China Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 84: China 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • EUROPE
    • TABLE 85: Europe Current & Future Analysis for Human Microbiome by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 and % CAGR
    • TABLE 86: Europe Historic Review for Human Microbiome by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 87: Europe 15-Year Perspective for Human Microbiome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2018 & 2027
    • TABLE 88: Europe Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 89: Europe Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 90: Europe 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 91: Europe Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 92: Europe Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 93: Europe 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 94: Europe Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 95: Europe Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 96: Europe 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • FRANCE
    • TABLE 97: France Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 98: France Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 99: France 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 100: France Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 101: France Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 102: France 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 103: France Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 104: France Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 105: France 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • GERMANY
    • TABLE 106: Germany Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 107: Germany Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 108: Germany 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 109: Germany Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 110: Germany Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 111: Germany 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 112: Germany Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 113: Germany Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 114: Germany 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • ITALY
    • TABLE 115: Italy Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 116: Italy Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 117: Italy 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 118: Italy Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 119: Italy Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 120: Italy 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 121: Italy Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 122: Italy Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 123: Italy 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • UNITED KINGDOM
    • TABLE 124: UK Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 125: UK Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 126: UK 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 127: UK Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 128: UK Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 129: UK 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 130: UK Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 131: UK Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 132: UK 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • REST OF EUROPE
    • TABLE 133: Rest of Europe Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 134: Rest of Europe Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 135: Rest of Europe 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 136: Rest of Europe Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 137: Rest of Europe Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 138: Rest of Europe 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 139: Rest of Europe Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 140: Rest of Europe Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 141: Rest of Europe 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • ASIA-PACIFIC
    • TABLE 142: Asia-Pacific Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 143: Asia-Pacific Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 144: Asia-Pacific 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 145: Asia-Pacific Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 146: Asia-Pacific Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 147: Asia-Pacific 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 148: Asia-Pacific Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 149: Asia-Pacific Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 150: Asia-Pacific 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • REST OF WORLD
    • TABLE 151: Rest of World Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 152: Rest of World Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 153: Rest of World 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 154: Rest of World Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 155: Rest of World Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 156: Rest of World 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 157: Rest of World Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 and % CAGR
    • TABLE 158: Rest of World Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 and % CAGR
    • TABLE 159: Rest of World 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027

IV. COMPETITION

  • Total Companies Profiled: 46